
    
      In this study, eligible subject will be randomized into study arm or control arm to accept
      study treatment. Subjects who randomized into control will have the opportunity to receive
      the treatment of carboplatin + paclitaxel-albumin therapy after confirmed disease
      progression. Treatment cycles of chemotherapy will be 2.
    
  